ES2172415A1 - Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. - Google Patents

Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Info

Publication number
ES2172415A1
ES2172415A1 ES200001916A ES200001916A ES2172415A1 ES 2172415 A1 ES2172415 A1 ES 2172415A1 ES 200001916 A ES200001916 A ES 200001916A ES 200001916 A ES200001916 A ES 200001916A ES 2172415 A1 ES2172415 A1 ES 2172415A1
Authority
ES
Spain
Prior art keywords
intraocular pressure
indole derivatives
reducing intraocular
pharmaceutical compositions
melatonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200001916A
Other languages
English (en)
Other versions
ES2172415B2 (es
Inventor
Just Jesus Pintor
Cerda Asuncion Peral
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to ES200001916A priority Critical patent/ES2172415B2/es
Priority to US09/915,486 priority patent/US6730707B2/en
Priority to CA002417489A priority patent/CA2417489A1/en
Priority to CN01815096A priority patent/CN1450896A/zh
Priority to KR10-2003-7001250A priority patent/KR20030046395A/ko
Priority to JP2002515255A priority patent/JP2004518612A/ja
Priority to ARP010103596A priority patent/AR035651A1/es
Priority to PCT/US2001/024220 priority patent/WO2002009702A2/en
Priority to EP01959427A priority patent/EP1307191A2/en
Priority to AU2001280984A priority patent/AU2001280984A1/en
Priority to MXPA03000729A priority patent/MXPA03000729A/es
Publication of ES2172415A1 publication Critical patent/ES2172415A1/es
Application granted granted Critical
Publication of ES2172415B2 publication Critical patent/ES2172415B2/es
Priority to US10/828,785 priority patent/US20040198803A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tratamiento del glaucoma y la hipertensión ocular por medio de un análogo de la melatonina. La presente invención describe un método para el tratamiento de la hipertensión ocular y del glaucoma mediante la administración de la sustancia comercial 5- metoxicarbonilamino-N-acetiltriptamina (5-MCA-NAT). La solución es aplicada preferentemente por vía tópica, pudiendo ser aplicada por medio de otros tipos de preparados como gotas de líquido, lavados de líquido, geles, ungüentos, sprays y liposomas.
ES200001916A 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. Expired - Fee Related ES2172415B2 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200001916A ES2172415B2 (es) 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US09/915,486 US6730707B2 (en) 2000-07-28 2001-07-25 Method for reducing intraocular pressure using indole derivatives
AU2001280984A AU2001280984A1 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
KR10-2003-7001250A KR20030046395A (ko) 2000-07-28 2001-07-27 인돌 유도체를 사용하여 안압을 감소시키는 방법
JP2002515255A JP2004518612A (ja) 2000-07-28 2001-07-27 インドール誘導体を用いて眼圧を下降させる方法
ARP010103596A AR035651A1 (es) 2000-07-28 2001-07-27 Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
CA002417489A CA2417489A1 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP01959427A EP1307191A2 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
CN01815096A CN1450896A (zh) 2000-07-28 2001-07-27 用吲哚衍生物降低眼内压的方法
MXPA03000729A MXPA03000729A (es) 2000-07-28 2001-07-27 Metodo para reducir la presion intraocular utilizando derivados de indol.
PCT/US2001/024220 WO2002009702A2 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
US10/828,785 US20040198803A1 (en) 2000-07-28 2004-04-20 Method for reducing intraocular pressure using indole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001916A ES2172415B2 (es) 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Publications (2)

Publication Number Publication Date
ES2172415A1 true ES2172415A1 (es) 2002-09-16
ES2172415B2 ES2172415B2 (es) 2003-11-16

Family

ID=8494491

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001916A Expired - Fee Related ES2172415B2 (es) 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Country Status (2)

Country Link
US (2) US6730707B2 (es)
ES (1) ES2172415B2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
ATE473740T1 (de) * 2002-08-29 2010-07-15 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen
JP3964417B2 (ja) * 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
US20090220516A1 (en) * 2005-06-22 2009-09-03 Alan Laties Neuroprotection of retinal ganglion cells
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
WO2010008883A1 (en) * 2008-06-24 2010-01-21 Qlt Plug Delivery, Inc. Combination treatment of glaucoma
US20130045992A1 (en) 2010-01-28 2013-02-21 President And Fellows Of Harvard College Compositions and Methods for Enhancing Proteasome Activity
US9089579B2 (en) 2011-01-19 2015-07-28 Topokine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
EP2707101B1 (en) 2011-05-12 2019-02-13 Proteostasis Therapeutics, Inc. Proteostasis regulators
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
MX2015006390A (es) 2012-11-21 2015-08-05 Topokine Therapeutics Inc Metodos y composiciones para incrementar localmente la grasa corporal.
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
NO2753788T3 (es) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
EP3907231A1 (en) * 2015-07-19 2021-11-10 Yeda Research and Development Co., Ltd. Selective inhibitors of alpha2-containing isoforms of na,k-atpase and use thereof for reducing intraocular pressure
KR20230061473A (ko) * 2020-09-02 2023-05-08 인베릭 바이오사이언시스 캐나다 인크. 니트로화된 실로시빈 유도체 및 5-ht2a 수용체를 조절하고 정신 장애를 치료하기 위한 이의 용도
WO2023044556A1 (en) * 2021-09-24 2023-03-30 Enveric Biosciences Canada Inc. Aminated psilocybin derivatives and methods of using
CN113880749B (zh) * 2021-10-11 2023-06-30 江南大学 化合物JNc-463的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393081A (en) * 1981-10-28 1983-07-12 Miles Laboratories, Inc. Methyl 3-acetamido-2-(5-methoxy-indol-3-yl) propanoate and hypotensive use thereof
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
WO1999023070A1 (en) * 1997-11-04 1999-05-14 St. Elizabeth's Medical Center Of Boston, Inc. N-acetylserotonin derivatives and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803218A (en) 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
AU616907B2 (en) * 1987-08-17 1991-11-14 Whitby Research, Inc. Melatonin analogues
EP0492903A1 (en) 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
US6071946A (en) 1994-10-21 2000-06-06 Adir Et Compagnie Tricyclic urea compounds
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2737725B1 (fr) 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
EP1050308A4 (en) * 1998-01-28 2002-09-04 Senju Pharma Co PROPHYLACTIC MEASURES OR REMEDIES AGAINST VISION DISORDERS
DE69924254D1 (de) 1998-07-16 2005-04-21 Univ Pennsylvania Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393081A (en) * 1981-10-28 1983-07-12 Miles Laboratories, Inc. Methyl 3-acetamido-2-(5-methoxy-indol-3-yl) propanoate and hypotensive use thereof
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
WO1999023070A1 (en) * 1997-11-04 1999-05-14 St. Elizabeth's Medical Center Of Boston, Inc. N-acetylserotonin derivatives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLINARI, E.J. y col. 2-[125I]Iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. European Journal of Pharmacology, 1996, Vol. 301, paginas 159-168. *

Also Published As

Publication number Publication date
ES2172415B2 (es) 2003-11-16
US6730707B2 (en) 2004-05-04
US20040198803A1 (en) 2004-10-07
US20020037887A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
ES2172415A1 (es) Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US5849761A (en) Peripherally active anti-hyperalgesic opiates
TW200733964A (en) (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
EA200201262A1 (ru) Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
DK1553953T3 (da) Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
HK1091418A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
ATE336247T1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
DE69930271T8 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ATE453395T1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
PL1806136T3 (pl) Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
ATE215824T1 (de) Mittel zur verminderung des augeninnendrucks

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020916

Kind code of ref document: A1

Effective date: 20020916

FG2A Definitive protection

Ref document number: 2172415B2

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20201105